SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Lymph nodes (C770-C779) are the usual primary sites; however, involvement in other sites is possible. If you have confirmation that the only involved site is something other than the lymph nodes, then code to that primary site. See Module 7.
Most patients present with stage II disease. B symptoms are encountered in approximately 40% of cases. Massive mediastinal disease is an adverse prognostic disease.
For more information on this neoplasm, see the NCI website: http://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq or http://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq